Global Cancer Monoclonal Antibodies Market 2017-2021


◆タイトル:Global Cancer Monoclonal Antibodies Market 2017-2021
◆調査・発行会社:Technavio (Infiniti Research Ltd.)
◆資料形式:PDF / 英語
Single User(1名利用)USD3,500 ⇒換算¥378,000見積依頼/購入/質問フォーム
Five User(~5名利用)USD4,500 ⇒換算¥486,000見積依頼/購入/質問フォーム
Enterprise License(全社内共有可)USD5,000 ⇒換算¥540,000見積依頼/購入/質問フォーム
※弊社H&Iグローバルリサーチ株式会社はTechnavio (Infiniti Research Ltd.)の日本における正規販売代理店です。





About Cancer Monoclonal AntibodiesThe mAbs, which are produced by genetic engineering, target antigens in cells, tissues, and organs. They are used in clinical applications to treat diseases with excellent efficacy and minimal side effects. Their MOA, absence of generic pathway, and therapeutic applications distinguish them from other targeted therapeutics.

Technavio’s analysts forecast the global cancer monoclonal antibodies market to grow at a CAGR of 10.86% during the period 2017-2021.

[Covered in this report]
The report covers the present scenario and the growth prospects of the global cancer monoclonal antibodies market for 2017-2021. To calculate the market size, the report considers the revenue generated from the sales of branded cancer mAbs and biosimilars used to treat cancer. It also considers the revenues to be generated from the sales of drugs that are expected to be launched into the market along with the decline in revenues from the patent expiries of the marketed drugs during the forecast period.

The market is divided into the following segments based on geography:
• Americas

Technavio’s report, Global Cancer Monoclonal Antibodies Market 2017-2021, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.

[Key vendors]
• F. Hoffmann-La Roche
• Amgen
• Bristol-Myers Squibb
• Takeda Pharmaceuticals

[Other prominent vendors]
• AbbVie
• ADC Therapeutics
• Agensys
• Argos Therapeutics
• Astellas Pharma
• AstraZeneca
• Bayer
• Biogen
• Biotech Pharmaceutical
• BioGenomics
• Boehringer Ingelheim
• Celldex Therapeutics
• Chugai Pharmaceutical
• CTI BioPharma
• Daiichi Sankyo
• Eli Lilly
• Fortress Biotech
• Genmab
• Immunomedics
• Intas Pharmaceuticals
• Janssen Biotech
• Kyowa Hakko Kirin
• Merck
• MedImmune
• Morphotek
• Neovii Biotech
• Novartis
• OncoMed Pharmaceuticals
• Pfizer
• Sanofi
• Seattle Genetics
• TG Therapeutics
• Xbiotech

[Market driver]
• Increase in demand for ADCs
• For a full, detailed list, view our report

[Market challenge]
• Complicated regulatory framework
• For a full, detailed list, view our report

[Market trend]
• Emergence of targeted and combination therapies
• For a full, detailed list, view our report

[Key questions answered in this report]
• What will the market size be in 2021 and what will the growth rate be?
• What are the key market trends?
• What is driving this market?
• What are the challenges to market growth?
• Who are the key vendors in this market space?
• What are the market opportunities and threats faced by the key vendors?
• What are the strengths and weaknesses of the key vendors?

※You can request one free hour of our analyst’s time when you purchase this market report. Details are provided within the report.


PART 01: Executive summary

PART 02: Scope of the report
• Market overview
• Assumptions
• Top-vendor offerings

PART 03: Market research methodology
• Research methodology
• Economic indicators

PART 04: Introduction
• Key market highlights

PART 05: mAbs: Overview
• Evolution of mAb therapeutics
• Conjugated cancer therapies using mAbs

PART 06: Timeline of mAbs for cancer

PART 07: Pipeline portfolio
• List of Phase III pipeline molecules
• List of Phase II pipeline molecules
• List of Phase I pipeline molecules

PART 08: Market landscape
• Market overview
• Five forces analysis

PART 09: Market segmentation by type of mAbs
• Naked mAbs
• Conjugated mAbs

PART 10: Market segmentation by MOA
• Immune system suppressors
• Kill or inhibit malignant cells
• Angiogenesis inhibitors
• Radiation therapy to cancer cells
• Delivering chemotherapy to cancer cells

PART 11: Geographical segmentation
• Cancer mAbs market in Americas
• Cancer mAbs market in EMEA
• Cancer mAbs market in APAC

PART 12: Market drivers
• Increase in demand for ADCs
• Special regulatory drug designations
• Advanced technological innovations
• Increase in industry-academia collaborations

PART 13: Impact of drivers

PART 14: Market challenges
• Complicated regulatory framework
• Absence of adequate diagnosis and screening procedures
• High manufacturing costs coupled with stringent regulations
• Threat from chemotherapy and off-label drugs

PART 15: Impact of drivers and challenges

PART 16: Market trends
• Emergence of targeted and combination therapies
• Joint ventures and partnerships for R&D
• Advent of biosimilars expected to improve the treatment rates

PART 17: Vendor landscape
• Competitive scenario
• Key news
• Other prominent vendors

PART 18: Key vendor analysis
• Amgen
• Bristol-Myers Squibb
• F. Hoffmann-La Roche
• Takeda Pharmaceuticals

PART 19: Appendix
• List of abbreviations

PART 20: Explore Technavio

[List of Exhibits]

Exhibit 01: Offerings
Exhibit 02: Key buying criteria for cancer mAbs 2016
Exhibit 03: Impact of key customer segments on the market 2016
Exhibit 04: Comparison of small molecule and mAbs
Exhibit 05: Preparation of mAbs
Exhibit 06: Types of mAbs
Exhibit 07: Targeted mechanisms of cancer mAbs
Exhibit 08: Timeline of mAbs for cancer
Exhibit 09: Global cancer mAbs market: Share of pipeline molecules
Exhibit 10: Global cancer mAbs market: Phase III pipeline molecules
Exhibit 11: Global cancer mAbs market: Phase II pipeline molecules
Exhibit 12: Global cancer mAbs market: Phase I pipeline molecules
Exhibit 13: Overview of global cancer mAb market 2016-2021
Exhibit 14: Global cancer mAbs market snapshot: Developed and emerging markets 2016
Exhibit 15: Global cancer mAbs market 2016-2021 ($ billions)
Exhibit 16: A few of patient assistance programs offered by various drugs
Exhibit 17: Few awareness programs for various cancers
Exhibit 18: Patent expiries of top-selling mAbs by 2021 in US
Exhibit 19: Patent expiries of top selling mAbs by 2021 in Europe
Exhibit 20: Annual treatment cost per patient for various oncology drugs 2015
Exhibit 21: Analysis of global cancer mAbs market by type of application
Exhibit 22: Five forces analysis
Exhibit 23: Market share of global cancer mAbs market by type of mAbs:
Exhibit 24: US FDA- and EU-approved naked cancer mAbs
Exhibit 25: Currently available conjugated mAbs
Exhibit 26: Market segmentation by MOA
Exhibit 27: Global cancer mAbs market revenue by geography 2016-2021 ($ billions)
Exhibit 28: Overview of cancer mAbs market in Americas
Exhibit 29: Cancer mAbs market in Americas 2016-2021 ($ billions)
Exhibit 30: Cancer mAb market in Americas: Opportunity analysis
Exhibit 31: Cancer mAbs market in Americas by country 2015
Exhibit 32: Cancer mAbs market in US 2016-2021 ($ billions)
Exhibit 33: Overview of cancer mAbs market in EMEA
Exhibit 34: Cancer mAbs market in EMEA 2016-2021 ($ billions)
Exhibit 35: Cancer mAbs market in EMEA by country 2016
Exhibit 36: Cancer mAb market in EMEA: Opportunity analysis
Exhibit 37: Overview of cancer mAbs market in APAC
Exhibit 38: Cancer mAbs market in APAC 2016-2020 ($ billions)
Exhibit 39: Cancer mAb market in APAC: Opportunity analysis
Exhibit 40: Timeline of ADCs
Exhibit 41: ADC molecules under clinical trials
Exhibit 42: Special regulatory designations approved by US FDA
Exhibit 43: Special regulatory designations approved by EU
Exhibit 44: Advances in ADCs technology
Exhibit 45: Advances in engineered and bispecific antibodies technology
Exhibit 46: Impact of drivers
Exhibit 47: Impact of drivers and challenges
Exhibit 48: Expected combination regimen launches in oncology
Exhibit 49: Market share analysis 2016
Exhibit 50: YoY sales comparison of top cancer mAbs 2013-2015 ($ billions)
Exhibit 51: Competitive assessment of vendors
Exhibit 52: Key vendors: Geographical presence 2015
Exhibit 53: Amgen: Key highlights
Exhibit 54: Amgen: Strength assessment
Exhibit 55: Amgen: Strategy assessment
Exhibit 56: Amgen: Opportunity assessment
Exhibit 57: Bristol-Myers Squibb: Key highlights
Exhibit 58: Bristol-Myers Squibb: Strength assessment
Exhibit 59: Bristol-Myers Squibb: Strategy assessment
Exhibit 60: Bristol-Myers Squibb: Opportunity assessment
Exhibit 61: Hoffmann-La Roche: Key highlights
Exhibit 62: F. Hoffmann-La Roche: Strength assessment
Exhibit 63: F. Hoffmann-La Roche: Strategy assessment
Exhibit 64: F. Hoffmann-La Roche: Opportunity assessment
Exhibit 65: Takeda Pharmaceuticals: Highlights
Exhibit 66: Takeda Pharmaceuticals: Strength assessment
Exhibit 67: Takeda Pharmaceuticals: Strategy assessment
Exhibit 68: Takeda Pharmaceuticals: Opportunity assessment


F. Hoffmann-La Roche, Amgen, Bristol-Myers Squibb, Takeda Pharmaceuticals, AbbVie, ADC Therapeutics, Agensys, Argos Therapeutics, Astellas Pharma, AstraZeneca, Bayer, Biogen, Biotech Pharmaceutical, BioGenomics, Boehringer Ingelheim, Celldex Therapeutics, Chugai Pharmaceutical, CTI BioPharma, Daiichi Sankyo, Eli Lilly, Fortress Biotech, Genmab, Immunomedics, Intas Pharmaceuticals, Janssen Biotech, Kyowa Hakko Kirin, Merck, MedImmune, Morphotek, Neovii Biotech, Novartis, OncoMed Pharmaceuticals, Pfizer, Sanofi, Seattle Genetics, TG Therapeutics, and Xbiotech.